

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 04/07/2020

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai-400001

Scrip Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. Saturday, 04th day of July, 2020 (commenced at 12:30 P.M. and concluded at 04:30 P.M.), has inter alia approved and passed the following resolutions:

1. Consideration and Approval of the Audited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended 31st March, 2020. **(Copy Enclosed)**
2. The Board considered and took on record, the Audit Report on Financial Results for the quarter and year ended 31st March, 2020 as placed by the Statutory Auditor of the Company. **(Copy Enclosed)**
3. Declaration of unmodified opinion on Auditor's Report on annual financial results for the quarter and year ended 31st March, 2020. **(Copy Enclosed)**
4. Declaration of Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter ended March 31, 2020. **(Copy Enclosed)**

Kindly take the above information on your records.

Thanking you,

For Raymed Labs Limited

Nisha Goyal

Director

DIN: 02710946

Place: Noida



A. Kay Mehra & Co.

CHARTERED ACCOUNTANTS

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

**INDEPENDENT AUDITORS' REPORT ON STATEMENT OF AUDITED
STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON
31ST MARCH, 2020**

**TO
THE BOARD OF DIRECTORS OF
RAYMED LABS LIMITED**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of RAYMED LABS Limited ("the Company") for the quarter ended March 31, 2020 and for the year ended March 31, 2020 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Regulation).

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard;
and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2020 and for the year ended March 31, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the

Jeepal Gera

Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Deepak



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Deepak



Other Matter

The accompanying Result with regard to management's evaluation of uncertainty due to outbreak of COVID-19 and its impact on future operation of the Company. Our opinion is not modified in respect of this matter.

The Statement includes the results for the Quarter ended March 31,2020 being the balancing figure between audited figures in respect of the full financial year ended March 31, 2020 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our report is not modified in respect of these matters.

For A. Kay. Mehra & Co.
Chartered Accountants

FRN: (050004C)



CA Deepak Suneja
Membership No- 501957

Date: 04-July-2020

UDIN - 20501957AAAHC4727

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2020

Amt. (In Lakhs)

Particulars	Quarter Ended			Year Ended	
	31st March, 2020	31st Dec, 2019	31st March, 2019	31st March, 2020	31st March, 2019
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	0.00	0.00	0.00	0.00	0.00
II. Other Income	0.33	0.33	0.33	1.32	1.26
III. Total Income (I +II)	0.33	0.33	0.33	1.32	1.26
IV. Expenses					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.23	0.23	0.60	1.60	1.35
Finance Costs	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.15	0.15	0.16	0.60	0.64
Other Expenses	0.49	0.22	0.52	1.44	1.68
Total Expenses (IV)	0.86	0.60	1.27	3.64	3.66
V. Profit/(Loss) before exceptional items and tax (III- IV)	-0.53	-0.27	-0.94	-2.32	-2.40
VI. Exceptional items	0.00	2.36	0.00	3.25	2.95
VII. Profit/(Loss) before tax (V-VI)	-0.53	-2.63	-0.94	-5.57	-5.35
VIII. Tax Expense					
(1) Current tax	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-0.53	-2.63	-0.94	-5.57	-5.35
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-0.53	-2.63	-0.94	-5.57	-5.35
XIV. Other Comprehensive Income					
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	-0.53	-2.63	-0.94	-5.57	-5.35
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)					
XVI. Paid up Equity Share Capital (Face Value of Rs. 10/- Each)	427.35	427.35	427.35	427.35	427.35
XVII. Other Equity	-	-	-	-625.76	-620.19
XIX. Earnings per equity share (for continuing operation):					
(1) Basic	-0.01	-0.06	-0.02	-0.13	-0.13
(2) Diluted	-0.01	-0.06	-0.02	-0.13	-0.13
XX. Earnings per equity share (for discontinued operation):					
(1) Basic	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00
XXI. Earnings per equity share (for discontinued & continuing operations)					
(1) Basic	-0.01	-0.06	-0.02	-0.13	-0.13
(2) Diluted	-0.01	-0.06	-0.02	-0.13	-0.13

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 04th, July 2020. The Statutory Auditors have carried out their audit for the above results.
- The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.
- The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year up to March 31, 2020 and the unaudited published year-to-date figures up to December 31, 2019, being the date of the end of the third quarter of the financial year which were subjected to limited review.
- The COVID -19 pandemic is rapidly spreading throughout the world. The Company has evaluated impact of this pandemic on its business operations and financial position and based on its review of current indicators of future economic conditions, there is no significant impact on its financial results as at 31st March 2020.

For Raymed Labs Limited

Nisha Goyal
 Director
 DIN: 02710946
 Add: 103 Emperor 1, Supertech Emerald Court,
 Sector 93A Noida, UP – 201304

Date: 04.07.2020
 Place : Noida

Statement of Audited Standalone Assets and Liabilities As At March 31, 2020

Particulars	Amount (In Lakhs)	
	As at 31st March, 2020	As at 31st March, 2019
	(Audited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	16.68	17.29
(b) Financials Assets-		
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.00	0.00
(iv) Other	0.00	0.00
(c) Deferred tax assets (net)	0.00	0.00
(d) Other non-current assets	0.00	0.00
Current Assets		
(a) Inventories	0.00	0.00
(b) Financials Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	2.49	2.49
(iii) Cash and cash equivalents	0.11	0.14
(iv) Bank Balance other than (iii) above	0.03	0.03
(v) Loans	6.10	6.10
(vi) Others	0.00	0.45
(c) Current tax Assets	0.00	0.00
(d) Other current Assets	0.28	0.00
TOTAL ASSETS	25.70	26.50
EQUITY AND LIABILITIES		
Equity-		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-625.76	-620.19
Liabilities		
Non -Current liabilities		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liabilities	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deferred Tax Liabilities (net)	0.00	0.00
(d) Other Non-Current Liabilities	0.00	0.00
Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	201.95	199.85
(ii) Trade Payables	5.54	5.54
(iii) Other Financial liabilities	5.00	5.00
(b) Other current liabilities	11.61	8.95
(c) provisions	0.00	0.00
(d) Current Tax Liabilities	0.00	0.00
TOTAL EQUITY AND LIABILITIES	25.70	26.50

For Raymed Labs Limited

Nisha Goyal
 Director
 DIN: 02710946
 Add: 103 Emperor 1, Supertech Emerald Court,
 Sector 93A Noida, UP – 201304

Date: 04.07.2020
 Place : Noida

Raymed Labs Limited
Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,
Uttar Pradesh, CIN: L24111UP1992PLC014240
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com,
Tel: 0120-2426900, 9412700300

AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2020

<i>Particulars</i>	Year ended March 31 2020 (Audited)	Year ended March 31 2019 (Audited)
Cash flow from Operating Activities		
Profit Before Tax	-5.57	-5.35
Adjustments for		
Depreciation and Amortisation Expense	0.60	0.64
Finance Costs	-	-
Interest Income on Fixed Deposits and Security Deposits measured at Amortised Cost	-	-
Dividend Income on Current Investments	-	-
Net (Gain) on Sale of Current Investments	-	-
Net Unrealised (Gain) / Loss on Foreign Currency Transactions and Translations	-	-
Share Based Payments	-	-
Fair Valuation (Gain)/ loss on Derivative Financial Instruments	-	-
Bad debts Written off	-	-
Allowances for Doubtful Trade Receivables (Expected Credit Loss Allowance)	-	-
Net loss on Disposal / Write off of Property, Plant, Equipment and Intangible Assets	-	-
Operating Profit Before Working Capital Changes	-4.97	-4.72
Changes in Working Capital		
Adjustments for (Increase) / Decrease in Operating Assets		
Loans to Employees	-	-
Security Deposits	-	-
Other Non-Current Assets	-	-
Trade Receivables	-	-
Other Financial Assets	-	-
Other Current Assets	0.17	0
Inventories	-	-
Adjustments for Increase / (Decrease) in Operating Liabilities		
Trade Payables	-	-
Other Financial Liabilities	2.10	1.05
Provisions	-	-
Other Current Liabilities	2.66	3.78
Cash Generated from Operations	-0.03	0.11
Taxes Paid	0	0
Net Cash Generated from Operating Activities	-0.03	0.11
Cash Flow from Investing Activities		
Payment for Purchase of Property, Plant, Equipment including Capital Work-in-Progress and Intangible Assets	-	-
Proceeds from Sale of Property, Plant, Equipment and Intangible Assets	-	-
Net Proceeds from Sale of Current Investments including investments under Scheme of Amalgamation	-	-
Interest Income Received	-	-
Dividend Income Received	-	-
Investment in Bank Deposits held as Margin Money	-	-
Net Cash Flow (Used in) Investing Activities	-	-
Cash Flow from Financing Activities		
Proceeds from Issuance of Equity Shares	-	-
Securities Premium received	-	-
Proceeds from Current Borrowings	-	-
Repayment of Current Borrowings	-	-
Repayment of Non-Current Borrowings	-	-
Repayment of Lease Liabilities	-	-
Dividend and Dividend Distribution Tax Paid	-	-
Finance Costs Paid including Interest on Lease Liabilities	-	-
Net Cash Flow (Used in) Financing Activities	-	-
Net Increase / (Decrease) in Cash and Cash Equivalents	-0.03	0.11
Cash and Cash Equivalents at beginning of the period	0.17	0.06
Changes in Cash and Cash Equivalents under Scheme of Amalgamation	0.00	0.00
Exchange Fluctuation Gain I (Loss) on Foreign Currency Bank Balances	0.00	0.00
Cash and Cash Equivalents at end of the period	0.14	0.17
Components of Cash and Cash Equivalents (At end of the period)	-	-
Balances with Banks on Current Accounts	0.03	0.03
Cash on Hand	0.11	0.14
Balances per statement of cash flows	0.14	0.17

Notes

2. Figures in brackets indicate cash out flow.
3. The above Cash flow statement has been prepared under the Indirect method set out in Ind AS-7 'Statement of Cash Flow' notified under the Companies (Indian Accounting Standards) Rules, 2015.

For Raymed Labs Limited

Nisha Goyal
Director
DIN: 02710946
Add: 103 Emperor 1, Supertech Emerald Court,
Sector 93A Noida, UP – 201304

Date: 04.07.2020
Place: Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 04.07.2020

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai-400001

Scrip Code: 531207

Sub: Declaration on Audit Report for the year ended 31st March, 2020

Dear Sir/Madam,

We hereby declare, on behalf of **Raymed Labs Limited** that Audit report in respect to Annual Audited financial Results for the period ended 31st March, 2020 submitted by **A Kay Mehra & Co.**, Statutory Auditor of the Company is with unmodified opinion of the Statutory Auditor.

Thanking you,

For Raymed Labs Limited

Nisha Goyal

Director

DIN: 02710946

Place: Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 04.07.2020

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai-400001

Scrip Code: 531207

Subject: Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter ended March 31, 2020

Sir/Madam,

With reference to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the disclosure of Statement of Deviation(s) or Variation(s) under the said regulation is not applicable to the Company.

Kindly take the above information for your records.

Thanking you,

For Raymed Labs Limited

NishaGoyal

Director

DIN: 02710946

Place: Noida